• AnaptysBio recently reported that the Delaware Chancery Court dismissed Tesaro’s anticipatory breach of contract claim over their Jemperli collaboration, while CEO Daniel Faga is set to discuss the company’s royalty assets at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on May 6, 2026.
• This legal outcome, combined with a stronger earnings outlook highlighted by an upgraded Zacks rank, strengthens AnaptysBio’s position around its Jemperli-related royalty rights.
• We’ll now examine how the court’s dismissal of Tesaro’s claim and AnaptysBio’s improved earnings outlook shape its broader investment narrative.

AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is AnaptysBio's Investment Narrative?

To own AnaptysBio today, you need to believe in its shift from a traditional biotech developer toward a lean royalty-focused model, with Jemperli at the center. The recent Delaware ruling in its favor does not end the dispute with Tesaro/GSK, but it removes the immediate threat of a royalty reduction and marginally improves visibility around Jemperli cash flows heading into the July 2026 trial. Coupled with improving earnings trends and a stronger Zacks rank, this helps explain the very large 1‑year total return, yet also sharpens the stock’s dependence on a single legal and commercial relationship. In the near term, the key catalysts are progress on the planned royalty spin-off, clarity on Jemperli enforcement, and capital allocation decisions around the sizeable buyback, while the main risk is that litigation or partner behavior still undermines the royalty stream investors now prize most.

Yet there is a specific legal overhang around Jemperli that shareholders cannot afford to ignore.

AnaptysBio's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Two Simply Wall St Community fair value views range from US$81.36 to US$351.35, underscoring how far apart expectations sit on AnaptysBio’s royalty potential. Set that against the still-unresolved Jemperli litigation risk discussed above and you can see why it pays to compare several perspectives before deciding how much of your portfolio, if any, belongs in this stock.

Explore 2 other fair value estimates on AnaptysBio - why the stock might be worth over 5x more than the current price!

Reach Your Own Conclusion

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your AnaptysBio research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free AnaptysBio research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AnaptysBio's overall financial health at a glance.

Searching For A Fresh Perspective?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Find 51 companies with promising cash flow potential yet trading below their fair value.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.